Skip NavigationSkip to Content
Return Return to Search Results

Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model

  1. Author:
    Zhu, Guangwei
    Zhao, Ming
    Han, Qinghong
    Tan, Yuying
    Sun, Y U
    Bouvet, Michael
    Clary, Bryan
    Singh,Shree Ram
    Ye, Jianxin
    Hoffman, Robert M

  2. Author Address

    AntiCancer, Inc., San Diego, CA, U.S.A., Department of Surgery, University of California, San Diego, CA, U.S.A., Department of Gastrointestinal Surgery 2 Section, The First Hospital Affiliated to Fujian Medical University, Fuzhou, P.R. China., Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, P.R. China., Basic Research Laboratory, National Cancer Institute, Frederick, MD, U.S.A. all@anticancer.com yejianxinfuyi@126.com singhshr@mail.nih.gov., Department of Gastrointestinal Surgery 2 Section, The First Hospital Affiliated to Fujian Medical University, Fuzhou, P.R. China all@anticancer.com yejianxinfuyi@126.com singhshr@mail.nih.gov., AntiCancer, Inc., San Diego, CA, U.S.A. all@anticancer.com yejianxinfuyi@126.com singhshr@mail.nih.gov.,
    1. Year: 2019
    2. Date: Dec
  2. Journal: Anticancer research
    1. 39
    2. 12
    3. Pages: 6463-6470
  4. Type of Article: Article
  5. ISSN: 0250-7005
  1. Abstract:

    The aim of the present study was to determine the efficacy of trabectedin combined with FOLFIRI (irinotecan, leucovorin and 5-fluorouracil) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (iPDOX) mouse model. A CRC tumor from a patient previously established in nude mice was implanted subcutaneously in transgenic green fluorescence protein (GFP)-expressing nude mice in order to label the tumor stromal cells with GFP. Mice were randomized into four groups: Group 1, untreated control; group 2, FOLFIRI; group 3, trabectedin alone; group 4, trabectedin plus FOLFIRI. Tumor width, length, and mouse body weight was measured twice every week. All three treatment groups showed inhibited tumor growth compared to the untreated control group. Only the combination of FOLFIRI and trabectedin arrested tumor growth. No significant changes was observed in body weight in any group. These findings suggest that the combination of trabectedin plus FOLFIRI has clinical potential for patients with CRC. Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.21873/anticanres.13860
  3. PMID: 31810910
  4. View record in Web of Science®
  5. WOS: 000522725300005
  6. PII : 39/12/6463

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel